NCT06393907

Brief Summary

A randomized controlled trial to evaluate the efficacy of hemostatic forceps and bipolar electrocautery probes in patient with high risk bleeding gastroduodenal ulcers.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 26, 2024

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 28, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 1, 2024

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 26, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 26, 2026

Completed
Last Updated

May 1, 2024

Status Verified

April 1, 2024

Enrollment Period

2 years

First QC Date

April 28, 2024

Last Update Submit

April 30, 2024

Conditions

Keywords

Hemostatic ForcepsBipolar Electrocautery ProbesGastroduodenal UlcerRebleedingHemostasisPeptic ulcer

Outcome Measures

Primary Outcomes (1)

  • Comparing hemostatic rate between hemostatic forceps and bipolar electrocautery probes

    When the bleeding stopped for at least 2 minutes, it is defined as successful hemostasis.

    During esophagogastroduodenoscopy

Secondary Outcomes (6)

  • Rebleeding rate at 7 days and 30 days after index intervention

    30 days

  • Survival rate after intervention

    30 days

  • Procedure time for achieving hemostasis

    During esophagogastroduodenoscopy

  • Number of units of infused blood

    30 days

  • Duration of hospitalization

    30 days

  • +1 more secondary outcomes

Study Arms (2)

Hemostatic forceps

EXPERIMENTAL

Hemostatic forceps will be used for control bleeding with electrocautery unit setting: 80 W, effect 4, soft coagulation mode for 1-2 seconds.

Device: Hemostatic Forceps

Bipolar electrocautery probes

ACTIVE COMPARATOR

Bipolar electrocautery probes will be used for control bleeding with electrocautery unit setting: effect 2, soft coagulation bipolar mode for 8-10 seconds.

Device: Bipolar Electrocautery Probes

Interventions

The experimental device will be used for control bleeding in high risk gastroduodenal ulcers.

Also known as: Coagrasper (Olympus, Tokyo, Japan)
Hemostatic forceps

The active comparator devices will be used for control bleeding in high risk gastroduodenal ulcers.

Also known as: Gold probe (Boston Scientific, Massachusetts, USA)
Bipolar electrocautery probes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The patient with upper gastrointestinal hemorrhage age ≥ 18 years old
  • The patient with gastroduodenal ulcer with indication for hemostatic intervention including 2.1 Forrest classification 1a (Active spurting) 2.2 Forrest classification 1b (Active oozing) 2.3 Forrest classification 2a (Non-bleeding visible vessel; NBVV) 2.4 Forrest classification 2b (Adherent clot) with lesion underneath clot which need hemostatic intervention including active spurting, active oozing or non-bleeding visible vessel

You may not qualify if:

  • Uncorrectable hemostasis laboratory including serum platelet \< 50000 /mm3 or International Normalized Ratio (INR) \>1.5
  • Bleeding from cancerous gastroduodenal ulcer
  • The patient with history of gastric surgery
  • The patient with history of bleeding gastroduodenal ulcer within 30 days prior to enrollment
  • The patient with history of proton pump inhibitor allergy
  • Pregnant
  • The patient deny to participate in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of internal medicine siriraj hospital, Mahidol university

Bangkok Noi, Bangkok, 10700, Thailand

RECRUITING

Related Publications (11)

  • Charatcharoenwitthaya P, Pausawasdi N, Laosanguaneak N, Bubthamala J, Tanwandee T, Leelakusolvong S. Characteristics and outcomes of acute upper gastrointestinal bleeding after therapeutic endoscopy in the elderly. World J Gastroenterol. 2011 Aug 28;17(32):3724-32. doi: 10.3748/wjg.v17.i32.3724.

    PMID: 21990954BACKGROUND
  • Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. Lancet. 1974 Aug 17;2(7877):394-7. doi: 10.1016/s0140-6736(74)91770-x. No abstract available.

    PMID: 4136718BACKGROUND
  • ASGE technology committee; Parsi MA, Schulman AR, Aslanian HR, Bhutani MS, Krishnan K, Lichtenstein DR, Melson J, Navaneethan U, Pannala R, Sethi A, Trikudanathan G, Trindade AJ, Watson RR, Maple JT; ASGE Technology Committee Chair. Devices for endoscopic hemostasis of nonvariceal GI bleeding (with videos). VideoGIE. 2019 Jun 27;4(7):285-299. doi: 10.1016/j.vgie.2019.02.004. eCollection 2019 Jul.

    PMID: 31334417BACKGROUND
  • Asge Technology Committee; Conway JD, Adler DG, Diehl DL, Farraye FA, Kantsevoy SV, Kaul V, Kethu SR, Kwon RS, Mamula P, Rodriguez SA, Tierney WM. Endoscopic hemostatic devices. Gastrointest Endosc. 2009 May;69(6):987-96. doi: 10.1016/j.gie.2008.12.251. No abstract available.

    PMID: 19410037BACKGROUND
  • Arima S, Sakata Y, Ogata S, Tominaga N, Tsuruoka N, Mannen K, Shiraishi R, Shimoda R, Tsunada S, Sakata H, Iwakiri R, Fujimoto K. Evaluation of hemostasis with soft coagulation using endoscopic hemostatic forceps in comparison with metallic hemoclips for bleeding gastric ulcers: a prospective, randomized trial. J Gastroenterol. 2010 May;45(5):501-5. doi: 10.1007/s00535-009-0186-8. Epub 2009 Dec 25.

    PMID: 20033825BACKGROUND
  • Kim JW, Jang JY, Lee CK, Shim JJ, Chang YW. Comparison of hemostatic forceps with soft coagulation versus argon plasma coagulation for bleeding peptic ulcer--a randomized trial. Endoscopy. 2015 Aug;47(8):680-7. doi: 10.1055/s-0034-1391565. Epub 2015 Mar 2.

    PMID: 25730283BACKGROUND
  • Nunoue T, Takenaka R, Hori K, Okazaki N, Hamada K, Baba Y, Yamasaki Y, Kono Y, Seki H, Inokuchi T, Takemoto K, Taira A, Tsugeno H, Fujiki S, Kawahara Y, Okada H. A Randomized Trial of Monopolar Soft-mode Coagulation Versus Heater Probe Thermocoagulation for Peptic Ulcer Bleeding. J Clin Gastroenterol. 2015 Jul;49(6):472-6. doi: 10.1097/MCG.0000000000000190.

    PMID: 25083773BACKGROUND
  • Toka B, Eminler AT, Karacaer C, Uslan MI, Koksal AS, Parlak E. Comparison of monopolar hemostatic forceps with soft coagulation versus hemoclip for peptic ulcer bleeding: a randomized trial (with video). Gastrointest Endosc. 2019 Apr;89(4):792-802. doi: 10.1016/j.gie.2018.10.011. Epub 2018 Oct 17.

    PMID: 30342026BACKGROUND
  • Bianco MA, Rotondano G, Marmo R, Piscopo R, Orsini L, Cipolletta L. Combined epinephrine and bipolar probe coagulation vs. bipolar probe coagulation alone for bleeding peptic ulcer: a randomized, controlled trial. Gastrointest Endosc. 2004 Dec;60(6):910-5. doi: 10.1016/s0016-5107(04)02232-1.

    PMID: 15605005BACKGROUND
  • Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012 Mar;107(3):345-60; quiz 361. doi: 10.1038/ajg.2011.480. Epub 2012 Feb 7.

    PMID: 22310222BACKGROUND
  • Veitch AM, Radaelli F, Alikhan R, Dumonceau JM, Eaton D, Jerrome J, Lester W, Nylander D, Thoufeeq M, Vanbiervliet G, Wilkinson JR, Van Hooft JE. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Gut. 2021 Sep;70(9):1611-1628. doi: 10.1136/gutjnl-2021-325184.

    PMID: 34362780BACKGROUND

MeSH Terms

Conditions

Peptic Ulcer

Condition Hierarchy (Ancestors)

Duodenal DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesStomach Diseases

Study Officials

  • Uayporn Kaosombatwattana, MD

    Mahidol University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Uayporn Kaosombattwattana, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
The participants will be randomized for each intervention using sequentially numbered, opaque sealed envelopes after recruitment in the study. The care provider who uses the devices cannot be blinded.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Hemostatic Forceps versus Bipolar Electrocautery Probes
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor

Study Record Dates

First Submitted

April 28, 2024

First Posted

May 1, 2024

Study Start

March 26, 2024

Primary Completion

March 26, 2026

Study Completion

April 26, 2026

Last Updated

May 1, 2024

Record last verified: 2024-04

Locations